Description |
MAP-0004 is a proprietary orally inhaled version of dihydroergotamine, or DHE, intended to treat migraine. Study showed that MAP-0004 provided pain relief as early as within ten minutes of dosing, and that this relief was sustained through at least 24 hours. The study also demonstrated efficacy trends in treating nausea, photophobia and phonophobia. Based on these results, as well as independent research that concludes that patients prefer migraine therapies providing fast onset, pain relief, sustained pain relief and safety, the company believes that MAP-0004 has the potential to be a first-line therapy for migraine patients.
|
